更新于：2024-11-01

Angina, Stable

稳定型心绞痛

更新于：2024-11-01

基本信息

别名

ANGINA STABLE、Angina Pectori, Stable、Angina Pectoris, Stable

+ [28]

简介

Persistent and reproducible chest discomfort usually precipitated by a physical exertion that dissipates upon cessation of such an activity. The symptoms are manifestations of MYOCARDIAL ISCHEMIA.

关联

项与稳定型心绞痛相关的药物

Caplacizumab-YHDP

卡普赛珠单抗

靶点

vWF

作用机制

vWF抑制剂

在研机构

Sanofi-Aventis Australia Pty Ltd. [+4]

原研机构

Ablynx NV

在研适应症

血栓性血小板减少性紫癜 [+1]

非在研适应症

稳定型心绞痛 [+2]

最高研发阶段批准上市

首次获批国家/地区

欧盟 [+3]

首次获批日期2018-08-30

Erenumab (Genetical Recombination)

依瑞奈尤单抗

靶点

CGRP receptor

作用机制

CALCRL拮抗剂

在研机构

Novartis Pharmaceuticals Corp. [+7]

原研机构

Amgen, Inc.

在研适应症

偏头痛 [+1]

非在研适应症

稳定型心绞痛 [+10]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2018-05-17

Shexiang Tongxin Dropping Pills

麝香通心滴丸

靶点-

作用机制-

在研机构

内蒙古康恩贝药业有限公司圣龙分公司

原研机构

内蒙古康恩贝药业有限公司圣龙分公司

在研适应症

稳定型心绞痛

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2018-01-28

627

项与稳定型心绞痛相关的临床试验

NCT06657326 / Not yet recruitingN/A

Evaluation of the Efficacy (QCA) and Safety of the BioFreedom™ Ultra Drug Coated Stent in Patients With High Bleeding Risk and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

This study aims to demonstrate that the BioFreedom™ Ultra Drug Coated Stent (DCS) is non-inferior to the BioFreedom™ DCS, with respect to in-stent late lumen loss, and that it has safety characteristics similar to the BioFreedom™ DCS.

开始日期2024-12-01

申办/合作机构

Biosensors Europe SA

NCT06655779 / Not yet recruitingN/A

Performance of the Acoustic Based CADScor System in Coronary Artery Disease

The purpose of this study is to determine if the CAD Score, collected from the CADscore system, performs as well as the Coronary CTA in determining Coronary Artery Disease, in low to intermediate risk patients that are referred for coronary CTA.

开始日期2024-11-01

申办/合作机构

INTEGRIS Baptist Medical Center, Inc.

CTR20243537 / RecruitingN/A

铝镁匹林片（Ⅱ）在中国健康人群中空腹和餐后状态下单次给药的人体生物等效性临床试验

主要目的：以持证商为 Lion Corporation 的铝镁匹林片（Ⅱ）（商品名：BUFFERIN Combination Tab. A81，规格：每片含阿司匹林 81mg，重质碳酸镁 22mg，甘羟铝 11mg）为参比制剂，以湖南金圃医药科技有限公司研发的铝镁匹林片（Ⅱ）（规格：每片含阿司匹林 81mg，重质碳酸镁22mg，甘羟铝 11mg）为受试制剂，评价两种制剂在中国健康受试者中空腹和餐后状态下的生物等效性。次要目的：评价受试制剂与参比制剂在中国健康受试者中的安全性。

开始日期2024-10-11

申办/合作机构

湖南金圃医药科技有限公司

100 项与稳定型心绞痛相关的临床结果

登录后查看更多信息

100 项与稳定型心绞痛相关的转化医学

登录后查看更多信息

0 项与稳定型心绞痛相关的专利（医药）

登录后查看更多信息

10,663

项与稳定型心绞痛相关的文献（医药）

2024-12-31·Scandinavian Cardiovascular Journal

Atrial fibrillation incidence after coronary artery bypass graft surgery and percutaneous coronary intervention: the prospective AFAF cohort study

Article

作者: Fengsrud, Espen ; Wickbom, Anders ; Kalm, Torbjörn ; Engdahl, Johan ; Alfredsson, Joakim ; Ahlsson, Anders

Objectives. Atrial fibrillation is a common arrhythmia in patients with ischemic heart disease. This study aimed to determine the cumulative incidence of new-onset atrial fibrillation after percutaneous coronary intervention or coronary artery bypass grafting surgery during 30 days of follow-up. Design. This was a prospective multi-center cohort study on atrial fibrillation incidence following percutaneous coronary intervention or coronary artery bypass grafting for stable angina or non-ST-elevation acute coronary syndrome. Heart rhythm was monitored for 30 days postoperatively by in-hospital telemetry and handheld thumb ECG recordings after discharge were performed. The primary endpoint was the cumulative incidence of atrial fibrillation 30 days after the index procedure. Results. In-hospital atrial fibrillation occurred in 60/123 (49%) coronary artery bypass graft and 0/123 percutaneous coronary intervention patients (p < .001). The cumulative incidence of atrial fibrillation after 30 days was 56% (69/123) of patients undergoing coronary artery bypass grafting and 2% (3/123) of patients undergoing percutaneous coronary intervention (p < .001). CABG was a strong predictor for atrial fibrillation compared to PCI (OR 80.2, 95% CI 18.1-354.9, p < .001). Thromboembolic stroke occurred in-hospital in one coronary artery bypass graft patient unrelated to atrial fibrillation, and at 30 days in two additional patients, one in each group. There was no mortality. Conclusion. New-onset atrial fibrillation during 30 days of follow-up was rare after percutaneous coronary intervention but common after coronary artery bypass grafting. A prolonged uninterrupted heart rhythm monitoring strategy identified additional patients in both groups with new-onset atrial fibrillation after discharge.

2024-12-01·Current Problems in Cardiology

Effects of traditional Chinese exercise on physical and mental health and quality of survival in patients with stable angina pectoris: A meta-analysis

Review

作者: Zhang, Chao ; Pan, Chunguang ; Wang, Lin ; Zhou, Xinchu ; Tang, Danfeng ; Dai, Fei

OBJECTIVECoronary heart disease (CHD) poses a significant threat to patients' health, with stable angina pectoris (SAP) being prevalent among individuals with CHD. This study aims to evaluate the effects of Traditional Chinese Exercise (TCE) on the physical and mental well-being, as well as the quality of life, of patients suffering from SAP.METHODSWe searched databases including China National Knowledge Infrastructure (CNKI), Wanfang, China Science and Technology Journal Database, PubMed, Web of Science, Cochrane and Embase for randomised controlled trials evaluating the effects of TCE on patients with SAP. Effect sizes and heterogeneity were calculated using RevMan 5.3 software.RESULTSA total of 14 studies involving 1,288 participants were included in the analysis. Most studies were assessed to have a moderate risk of bias. The pooled results indicated that TCE significantly improved the 6-Minute Walk Test scores of patients with SAP (MD = 35.48, 95 % CI: 23.66-47.29, P < 0.001), enhanced scores across various dimensions of the Seattle Angina Questionnaire (P < 0.05), and reduced levels of depression (MD = -6.32, 95 % CI: -9.13 to -3.51, P < 0.001) and anxiety (MD = -6.41, 95 % CI: -9.18 to -3.64, P < 0.001) among SAP patients. Additionally, the Egger's test revealed no significant publication bias across the outcomes (P > 0.05).CONCLUSIONTCE significantly enhances the physical and mental health of SAP patients, leading to improved quality of life. Future studies with larger sample sizes and high methodological quality are needed to further evaluate the clinical efficacy of TCE.

2024-12-01·Hormones

Testosterone therapy for functional hypogonadism in middle-aged and elderly males: current evidence and future perspectives

Review

作者: Theodorakis, Nikolaos ; Feretzakis, Georgios ; Verykios, Vassilios S ; Polymeris, Antonis ; Nikolaou, Maria ; Vamvakou, Georgia

Population aging is a global phenomenon driving research focus toward preventing and managing age-related disorders. Functional hypogonadism (FH) has been defined as the combination of low testosterone levels, typically serum total testosterone below 300-350 ng/dL, together with manifestations of hypogonadism, in the absence of an intrinsic pathology of the hypothalamic-pituitary-testicular (HPT) axis. It is usually seen in middle-aged or elderly males as a product of aging and multimorbidity. This age-related decline in testosterone levels has been associated with numerous adverse outcomes. Testosterone therapy (TTh) is the mainstay of treatment for organic hypogonadism with an identifiable intrinsic pathology of the HPT axis. Current guidelines generally make weak recommendations for TTh in patients with FH, mostly in the presence of sexual dysfunction. Concerns about long-term safety have historically limited TTh use in middle-aged and elderly males with FH. However, recent randomized controlled trials and meta-analyses have demonstrated safe long-term outcomes regarding prostatic and cardiovascular health, together with decreases in all-cause mortality and improvements in various domains, including sexual function, body composition, physical strength, bone density, and hematopoiesis. Furthermore, there are numerous insightful studies suggesting additional benefits of TTh, for instance in cardio-renal-metabolic conditions. Specifically, future trials should investigate the role of TTh in improving symptoms and prognosis in various clinical contexts, including sarcopenia, frailty, dyslipidemia, arterial hypertension, diabetes mellitus, fracture risk, heart failure, stable angina, chronic kidney disease, mood disorders, and cognitive dysfunction.

项与稳定型心绞痛相关的新闻（医药）

2024-10-31

·米内网

【市场】50亿高血压药，黄海制药获批了

精彩内容日前，国家药监局官网显示，青岛黄海制药的硝苯地平控释片以仿制4类报产获批，视同过评。米内网数据显示，硝苯地平控释片在2023年中国三大终端六大市场（统计范围详见本文末）销售额超过50亿元，是高血压化药TOP1产品。来源：米内网一键检索硝苯地平控释片是由拜耳研发，用于治疗高血压、冠心病，慢性稳定型心绞痛（劳累性心绞痛）。近年中国零售药店终端硝苯地平控释片销售情况（单位：万元）来源：米内网格局数据库硝苯地平控释片在2023年中国三大终端六大市场销售额超过50亿元，是高血压化药TOP1产品，拜耳的市场份额占比最大。院内市场（公立医院终端+公立基层医疗终端）是主力销售渠道，而院外市场（零售药店终端：城市实体药店+网上药店）则持续增长。米内网数据显示，硝苯地平控释片有26家企业拥有生产批文，青岛黄海制药、亚宝药业集团、乐普药业、扬子江药业集团等25家过评，山东新时代药业和复星医药(徐州)以仿制4类报产在审，获批后视同过评。青岛黄海制药高血压化药产品批文情况来源：米内网中国上市药品（MID）数据库截至目前，青岛黄海制药在高血压化药领域拥有硝苯地平控释片、硝苯地平缓释片(Ⅱ)、奥美沙坦酯片、坎地沙坦酯胶囊等6款产品生产批文；沙库巴曲缬沙坦钠片报产在审，2023年中国三大终端六大市场沙库巴曲缬沙坦钠片是30亿元级别的大品种，在高血压化药中位居第四。据了解，青岛黄海制药是一家研发、生产、销售缓控释制剂为主的高新技术企业，致力于为患者提供高质量的药品和慢病治疗解决方案。公司以打造中国缓控释制剂领军企业为战略目标，以心脑血管系统用药、内分泌用药、神经类疾病用药和抗肿瘤药物为产业重心。资料来源：国家药监局官网、米内网数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

一致性评价上市批准

2024-10-26

·PRNewswire

ADVANCED NANOTHERAPIES ANNOUNCES POSITIVE RESULTS IN ITS FIRST-IN-HUMAN TRIAL AND PLANS FOR U.S. EARLY FEASIBILITY STUDY FOR SIRPLUX™ DUO DRUG-COATED BALLOON

First-of-its-kind Dual-Drug Therapy for Coronary De Novo Disease Moves Toward U.S. Clinical Phase Novel Nanoparticle Technology Platform Aims to Deliver Two Proven Drugs for Vessel Patency and Restenosis Prevention SANTA CLARA, Calif., Oct. 26, 2024 /PRNewswire/ -- Advanced NanoTherapies (ANT), a clinical-stage medical device company committed to solving the most significant challenges in vascular disease through innovative applications of nanotechnology, announced positive results from its first-in-human (FIH) trial evaluating the next-generation SirPlux™ Duo Drug-Coated Balloon (DCB). The Company also announced plans to proceed towards executing its U.S. early feasibility study (EFS), known as DYNAMIC DUO I, to evaluate the safety and performance of the SirPlux™ Duo DCB in de novo coronary lesions. SirPlux™ Duo DCB delivers a synergistic dual-drug therapy of sirolimus and paclitaxel and is engineered for vessel patency and restenosis prevention. Continue Reading SirPlux™ Duo Drug-Coated Balloon (DCB) "The innovative drug delivery platform of the SirPlux Duo DCB is poised to redefine how coronary disease is treated," stated Dr. Bernardo Cortese, MD, FESC, FSCAI, Director, Interventional Coronary Center, University Hospitals and Professor of Medicine, Case Western Reserve. "By combining two proven drugs with the novel nanoparticle technology, SirPlux Duo DCB aims to minimize drug flaking, deliver sustained drug therapy at therapeutic levels, and get the best characteristics of the two drugs, theoretically making it a strong front-line device alternative to current DCBs or drug-eluting stents." SirPlux Duo DCB is the only therapy designed to deliver sirolimus and paclitaxel simultaneously to inhibit cell growth at a higher potency and efficient dose. ANT's novel nanoparticle drug encapsulation and delivery platform is designed to provide the two drugs with safe, reliable, and sustained long-term in-tissue bioavailability with no stent burden. "We are thrilled to take this next step in further validating the clinical performance of SirPlux™ Duo DCB, a novel technology licensed from the Cleveland Clinic," said Marwan Berrada-Sounni, Co-founder and CEO of ANT. "Moving forward with our DYNAMIC DUO I EFS aligns with our vision of advancing nanotechnology-driven solutions that combine the power of sirolimus and paclitaxel to offer a safe and prolonged therapy without leaving a permanent implant behind." The planned DYNAMIC DUO I EFS study is a prospective, multi-center, non-randomized study that will enroll and treat symptomatic stable angina, unstable angina, or NSTEMI patients with de novo coronary lesions with reference vessel diameters of 2 to 4 mm. The results from this study will inform the Company on how to advance its clinical programs to broader commercialization plans in the U.S. and global markets. About Advanced NanoTherapies (ANT) Advanced NanoTherapies, Inc., a member of the T45 Labs portfolio, is a highly specialized medical device company developing a nanoparticle technology-based platform for drug delivery. The Company focuses on minimally invasive cardiovascular applications to bring a safer therapeutic option to patients with arterial disease. The company's first product is the SirPlux Duo Drug-Coated Balloon (DCB), a next-generation front-line therapy for minimally invasive catheter interventions. To learn more about Advanced NanoTherapies, visit : Products are currently in development and are not available for sale. SOURCE Advanced NanoTherapies WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024-10-14

·GlobeNewswire-Health Care

HeartFlow to Present Latest Data on AI-Enabled Coronary Artery Disease Management at TCT 2024

Long-term outcomes data from ADVANCE-DK Registry with HeartFlow FFRCT and Plaque Analysis and ongoing clinical studies highlighting CCTA and FFRCT diagnostic pathway to be discussed in six presentations New data build upon the growing body of clinical evidence supporting non-invasive FFRCT technology and plaque analysis in the diagnosis and management of coronary artery disease MOUNTAIN VIEW, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- HeartFlow, the global leader in non-invasive artificial intelligence (AI) heart care solutions, today announced it will present seven-year data from the ADVANCE-DK study, a subset from the larger ADVANCE Registry, which evaluated utility and clinical outcomes of HeartFlow’s AI-enabled FFRCT and Plaque Analysis in clinically stable, symptomatic patients with coronary artery disease (CAD). Data from the ADVANCE-DK study and other clinical studies will be presented at the 36th annual Transcatheter Cardiovascular Therapeutics® (TCT) conference, which will take place October 27-30, 2024 in Washington, D.C. “The ADVANCE registry helps us better understand whether more complete revascularization, as defined by FFRCT, is associated with improved long-term cardiovascular outcomes,” said Campbell Rogers, M.D., F.A.C.C., Chief Medical Officer of HeartFlow. “Three-year data from this registry confirmed that patients with both abnormal FFRCT and high plaque burden had two-and-a-half to three times greater risk of adverse cardiac events compared to patients with only abnormal FFRCT or high plaque volume. We are excited to present seven-year data and build on our body of evidence demonstrating FFRCT and AI-enabled plaque assessment as non-invasive approaches which can help physicians better quantify CAD risk in their patients.” At TCT, HeartFlow will also present: Late-breaking data evaluating the capacity of FFRCT and coronary computed tomography angiography (CCTA) to rule out significant lesions in high-risk non-ST elevation acute coronary syndromes (NSTE-ACS).Data from FUTURE-AS, an international, prospective, multicenter registry of patients with severe aortic stenosis (AS) referred for transcatheter aortic valve replacement (TAVR) being assessed for CAD with CCTA and FFRCT.New data from FASTTRACK-CABG, a single-arm, multicenter, prospective study assessing safety and feasibility of bypass surgery in patients with complex CAD solely based on CCTA combined with FFRCT.Data highlighting the value for pre-procedural planning of combining FFRCT, virtual percutaneous coronary intervention (PCI), and myocardial mass.Analysis of initial FFRCT-based virtual PCI for pre-procedural planning in the U.S. Details of each presentation are as follows: Title: Completeness of Revascularization by FFRCT and Long-term Prognosis in Stable Angina: A Seven-Year Follow-up of the ADVANCE-DK RegistryPresenter: Kristian Taekker Madsen, M.D., Ph.D.Date: Sunday, October 27, 2024Time: 7:30-8:45 AM EDTSession: TCT WorldLink Forum: Best Global Research in Coronary ImagingLocation: Presentation Theater 3, Innovation & Exhibit Hall (Halls A-C) Title: TCT 288: Comparative Analysis of FFR Derived From CCTA, Murray Law-Based Quantitative Flow Ratio and Quantitative Flow Ratio at Sequential Side Branches in Patients With Complex CAD: Insights From the FASTTRACK CABG StudyPresenter: Kotaro Miyashita, M.D.Date: Sunday, October 27, 2024Time: 9:00-9:50 AM EDTSession: Moderated Abstracts Station 2Location: Innovation & Exhibit Hall (Halls A-C) Title: TCT 172: Usefulness of FFRCT to Exclude Hemodynamically Significant Lesions in High-Risk NSTE-ACS Presenter: Georgios Tzimas, M.D.Date: Monday, October 28, 2024Time: 4:00-5:30 PM EDTSession: Moderated Abstracts Station 2Location: Innovation & Exhibit Hall (Halls A-C) Title: TCT 830: Feasibility and Utility of Anatomical and Physiological Evaluation of Coronary Disease With Cardiac CT in Severe Aortic Stenosis (FUTURE-AS Registry)Presenters: Abdul Rahman Ihdayhid, M.D., Ph.D.Moderators: Philippe PM Garot, M.D., Marie-France Poulin, M.D.Date: Tuesday, October 29, 2024Time: 8:00-9:00 AM EDTSession: TAVR and CAD - 1Location: Moderated Abstracts Station 5, Innovation & Exhibit Hall (Halls A-C) Title: TCT 221: Coronary Computed Tomography Angiography-Guided Bifurcation Percutaneous Coronary Intervention: Role of FFRCT Virtual PCI and Myocardial Mass for Pre-Procedural PlanningPresenters: Pedro Carvalho, M.D.Moderators: Hector M. Garcia-Garcia, M.D., Ph.D., John J. Lopez, M.D.Date: Tuesday, October 29, 2024Time: 2:00-3:00 PM EDTSession: Anatomy-derived Coronary Physiology – 2Location: Moderated Abstracts Station 2, Innovation & Exhibit Hall (Halls A-C) Title: TCT 96: Coronary Computed Tomography Angiography for Percutaneous Coronary Intervention: Initial US Experience With FFRCT-Based Virtual PCI for Pre-Procedural PlanningPresenters: Pedro Carvalho, M.D.Moderators: Louis A. Cannon, M.D., Christopher Irobunda. M.D.Date: Wednesday, October 30, 2024Time: 9:00-9:56 AM EDTSession: Novel Percutaneous TechniquesLocation: Moderated Abstracts Station 6, Innovation & Exhibit Hall (Halls A-C) Heartflow invites attendees to a lunch symposium, “Utilizing Coronary CTA & HeartFlow AI to Non-Invasively Assess Anatomy, Physiology and Plaque,” led by a panel of well-respected physicians including Ziad A. Ali, M.D., Suzanne J. Baron, M.D., Nick Curzen, M.D., Jimmy Lee Kerrigan, M.D. and Akiko Maehara, M.D. The symposium will take place on Tuesday, October 29, 2024, from 12:30-1:30 PM EDT in the FDA Theater, Innovation & Exhibit Hall (Halls A-C). About HeartFlow, Inc.HeartFlow is transforming precision coronary care with the only AI-powered, non-invasive integrated heart care solution across the CCTA pathway. As the pioneer of FFRCT, which is now supported by the ACC/AHA Chest Pain Guideline, HeartFlow continues to advance the diagnosis and management of CAD. HeartFlow’s suite of non-invasive technologies includes its FFRCT Analysis, RoadMap™ Analysis, and Plaque Analysis. More than 500 peer-reviewed publications have validated our approach and more importantly, our technologies have helped clinicians diagnose and manage over 250,000 patients. For more information, visit www.heartflow.com. Media ContactElliot Levymedia@heartflow.com Investor ContactNick Laudiconlaudico@heartflow.com

AHA会议